Navigation Links
EVICEL(TM) Fibrin Sealant (Human) Approved for General Hemostasis in Surgery

Indication positions EVICEL(TM) as the only aprotinin-free fibrin sealant

option for a broad range of surgical procedures.

SOMERVILLE, N.J., Jan. 10 /PRNewswire/ -- ETHICON, INC. announced today that the U.S. Food and Drug Administration has granted an expanded indication for EVICEL(TM) Fibrin Sealant (Human). The product is the first fibrin sealant to be indicated as an adjunct to hemostasis for use in patients undergoing surgery, when control of bleeding by standard surgical techniques is ineffective or impractical.

EVICEL(TM) is the only all-human plasma-derived fibrin sealant commercially available in the U.S. It does not contain aprotinin, which has been associated with adverse health effects. EVICEL(TM) is easy to use and readily available for time-sensitive needs in the operating room. The product is sold as a frozen liquid and requires less than one minute preparation time after thawing.

"In surgery, the success of the procedure can sometimes depend upon the surgeon's ability to control blood loss quickly and effectively," said R. Clement Darling III, M.D., head of the Division of Vascular Surgery at Albany Medical Center. "EVICEL(TM) has become an important element of hemostasis in many liver and vascular procedures. The expansion of its indication to general surgery will bring the benefits of this product to more surgeons and their patients," added Dr. Darling.

EVICEL(TM) is contraindicated in individuals known to have anaphylactic or severe systemic reaction to human blood products. As with all plasma-derived products, the risk of transmitting infectious agents cannot be completely eliminated. EVICEL(TM) should not be injected directly into the circulatory system or used for the treatment of severe or brisk arterial bleeding. Anaphylactic reactions may occur. No adverse events of this type were reported during the conduction of the clinical trials.

EVICEL(TM) was developed by ETHICON, INC. in collaboration with OMRIX Biopharmaceuticals.


ETHICON, INC., a Johnson & Johnson company, is a global medical device company that develops and markets surgical products for use in general surgery, wound management and women's health & urology. Johnson & Johnson Wound Management, a division of ETHICON, INC., offers a complete portfolio of topical and advanced hemostatic products including SURGICEL(R) Absorbable Hemostats, SURGIFOAM* Absorbable Gelatin Sponge, EVICEL(TM) Fibrin Sealant (Human), and SURGIFLO* Hemostatic Matrix with FlexTip. For more information about ETHICON, INC., please visit

* Trademark

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
2. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
3. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
4. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
5. Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
6. Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
7. Sinovac Announces Postponement of Annual General Meeting
8. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
9. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
10. CryoLife Names Philip Theodore as Vice President, General Counsel
11. 3SBio Inc. to Hold Annual General Meeting
Post Your Comments:
(Date:10/13/2015)... ... 2015 , ... SonaCare Medical, LLC, a pioneer in minimally ... novo clearance from the U.S. Food and Drug Administration (FDA) to market the ... is the first High Intensity Therapeutic Ultrasound (HITU) device to receive FDA regulatory ...
(Date:10/13/2015)... ... October 13, 2015 , ... The ... school age children in the areas of Science, Technology, Engineering and Mathematics. The ... national economy, and the program aims to increase the number of students who ...
(Date:10/12/2015)... BRUSSELS , Oct. 12, 2015  Amgen ... presented additional findings from an exploratory sub-study of the previously ... presented today in an oral plenary session at the American ... in Seattle . 2 ... The small exploratory sub-study data showed that, at month 12, ...
(Date:10/12/2015)... 2015  MiMedx Group, Inc. (NASDAQ: MDXG ), ... and patent-protected processes to develop and market advanced products ... Sports Medicine, Ophthalmic, and the Dental sectors of healthcare, ... filed against the Company has been dismissed by the ... and CEO, stated, "As we suspected, this case was ...
Breaking Biology Technology:
(Date:10/5/2015)... October 5, 2015 ... for NXT-ID, Inc. (NASDAQ: NXTD ), a biometric ... --> ) releases the ... NXTD ), a biometric authentication company focused on ... Technology Group ( ) releases the ...
(Date:9/30/2015)... 2015  The global glucose monitoring device and diabetes management ... a new report on the industry from Kalorama Information. Sales in ... market, followed by continuous glucose monitoring and sensor segment, according ... for these products in its latest report, The Global ... , ...
(Date:9/28/2015)... 28, 2015 The global ... USD 12.03 billion by 2020, growing at a CAGR ... as Backside Illumination (BSI) technique to improve picture quality ... period.      (Logo: , ... to reduce loss and, thus, reduce the noise interference ...
Breaking Biology News(10 mins):